The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA grants CTL019 Breakthrough Therapy Designation for adult patients with relapsed/refractory Diffuse Large B-Cell Lymphoma
On 18th April 2017, CTL019 (also known as tisagenlecleucel) was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with R/R DLBCL who have failed two or more previous therapies.
Novartis’ CTL019 is an investigational Chimeric Antigen Receptor (CAR) T-cell therapy and the Breakthrough Therapy Designation is based on early data from the phase II, single arm, multicenter JULIET study (NCT02445248). The trial is aiming to assess the safety and efficacy of CTL019 in adult patients with R/R DLBCL, it has an estimated enrollment of 130 patients, and the estimated primary completion date is January 2024.
CTL019 already holds Breakthrough Therapy Designation for pediatric and young adult patients with R/R B-cell Acute Lymphoblastic Leukemia (ALL).
References